» Articles » PMID: 31044523

Evaluating the Role of Janus Kinase Pathways in Platelet Homeostasis Using a Systems Modeling Approach

Overview
Publisher Wiley
Specialty Pharmacology
Date 2019 May 3
PMID 31044523
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Maintaining platelet homeostasis is important to avoid spontaneous bleeding and organ damage. Thrombopoietin, the primary regulator of platelet production, is affected by and acts in part via Janus kinase (JAK)-signal transducer and activator of transcription (STAT)-mediated mechanisms. Interleukin-6 is also partly responsible for inducing thrombopoietin production via the JAK-STAT pathway. Although current understanding suggests that JAK2 is a primary mediator of platelet regulation, the emerging data show that a JAK1-specific inhibitor resulted in the modulation of platelet numbers following dosing. To gain a mechanistic understanding, a model describing platelet regulation based on known physiology and JAK-STAT pathways was built. The model provides a tool to coalesce biological understanding of platelet physiology and an in silico experimental platform to explore drug effects on platelet homeostasis. In this article, we explain the model construction and demonstrate the use of JAK-inhibitor programs as informing probes of the physiology, gaining insights on dosing paradigms that avoid platelet-related safety concerns.

Citing Articles

Janus kinase inhibitors modify the fatty acid profile of extracellular vesicles and modulate the immune response.

Daza Zapata A, Alvarez K, Vasquez Duque G, Palacio J, Rojas Lopez M Heliyon. 2024; 10(3):e24710.

PMID: 38314280 PMC: 10837569. DOI: 10.1016/j.heliyon.2024.e24710.


Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials.

Kiladjian J, Vannucchi A, Gerds A, Gupta V, Verstovsek S, Egyed M Hemasphere. 2023; 7(11):e963.

PMID: 37908862 PMC: 10615557. DOI: 10.1097/HS9.0000000000000963.


Population pharmacokinetic-pharmacodynamic modelling of platelet time-courses following administration of abrocitinib.

Wojciechowski J, Malhotra B, Wang X, Fostvedt L, Valdez H, Nicholas T Br J Clin Pharmacol. 2022; 88(8):3856-3871.

PMID: 35342978 PMC: 9544602. DOI: 10.1111/bcp.15334.


Janus kinase inhibitors for the therapy of atopic dermatitis.

Traidl S, Freimooser S, Werfel T Allergol Select. 2021; 5:293-304.

PMID: 34532638 PMC: 8439108. DOI: 10.5414/ALX02272E.


Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program.

Simpson E, Silverberg J, Nosbaum A, Winthrop K, Guttman-Yassky E, Hoffmeister K Am J Clin Dermatol. 2021; 22(5):693-707.

PMID: 34406619 PMC: 8370859. DOI: 10.1007/s40257-021-00618-3.


References
1.
Hsu H, Tsai W, Jiang M, Ho C, HSU M, Ho C . Circulating levels of thrombopoietic and inflammatory cytokines in patients with clonal and reactive thrombocytosis. J Lab Clin Med. 1999; 134(4):392-7. DOI: 10.1016/s0022-2143(99)90154-3. View

2.
Harker L, Roskos L, Marzec U, Carter R, CHERRY J, SUNDELL B . Effects of megakaryocyte growth and development factor on platelet production, platelet life span, and platelet function in healthy human volunteers. Blood. 2001; 95(8):2514-22. View

3.
Kuter D . The physiology of platelet production. Stem Cells. 1996; 14 Suppl 1:88-101. DOI: 10.1002/stem.5530140711. View

4.
Santillan M, Mahaffy J, Belair J, Mackey M . Regulation of platelet production: the normal response to perturbation and cyclical platelet disease. J Theor Biol. 2000; 206(4):585-603. DOI: 10.1006/jtbi.2000.2149. View

5.
Kaser A, Brandacher G, Steurer W, Kaser S, Offner F, Zoller H . Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood. 2001; 98(9):2720-5. DOI: 10.1182/blood.v98.9.2720. View